Tenderwize
Wróć do wyszukiwania

Open-house discount agreement for Levothyroxin-Natrium

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Levothyroxin-Natrium, ATC H03AA01

58/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

58 / 100

Złożoność

54 / 100

Czynniki ryzyka

The buyer explicitly states that this is an open-house model and not a normal open procedure; standard procurement assu...

Contract documents must be submitted through the communication area in the DTVP portal, not through the offer area; mis...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive supply/discount agreement for Levothyroxin-Natrium, ATC H03AA01.
  • Open-house accession model with identical, pre-set contract terms for qualifying pharmaceutical companies.
Pokaż pełne podsumowanie

This is an open-house supply arrangement for pharmaceutical discount agreements on Levothyroxin-Natrium (ATC H03AA01) with AOK Bayern. It is not a competitive open procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract term starts earliest on 2026-05-01 and ends on 2028-04-30, with a final contract entry deadline of 2028-03-03 11:00. No estimated contract value is provided.

Ryzyka

The buyer explicitly states that this is an open-house model and not a normal open procedure; standard procurement assu...

Contract documents must be submitted through the communication area in the DTVP portal, not through the offer area; mis...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Signed declaration of reliability must be submitted.

Kryteria udzielenia

Lot 1

No lot-specific award criteria are stated; this appears to be an open-house accession model rather than a scored award process.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house discount agreement for Levothyroxin-Natrium

Single lot covering non-exclusive open-house discount agreements for the pharmaceutical product Levothyroxin-Natrium (ATC H03AA01). The buyer indicates that contracts are identical, non-individually negotiable, and open to all interested pharmaceutical companies meeting the stated suitability requirement. Performance is in Germany, Bayern (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Apr 2026 - Apr 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No lot-specific award criteria are stated; this appears to be an open-house accession model rather than a scored award process.

Termin

Deadline Mar 03, 2028

Szczegóły zamówienia

Data publikacji
15 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
180221-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30